dc.description.abstract |
Background: It is known that etiological structure of recurrent miscarriage has genetic, anatomical, infectious and immunological factors; however,
the cause of recurrent miscarriage in 50-60% of cases is not completely clear. Homocysteine is a sulfur-containing intermediate product in the normal
metabolism of methionine. Development mechanisms of vascular complications of hyperhomocysteinemia are currently being intensively studied.
Hyperhomocysteinemia affects a number of mechanisms involved in thrombogenesis including coagulation cascade, vessel-thrombocytic section,
oxidation-reduction reactions, endothelium, and vascular smooth muscle cells and is associated with an increased risk of adverse outcomes in pregnancy.
Materials and methods: The study included 50 women who had experienced the loss of at least two consecutive pregnancies. The level of the total serum
homocysteine was measured via the chemiluminescent method.
Results: We found that plasma homocysteine concentration < 10 μmol/l was found in 16 patients (32,0%, 95% CI 19,07 – 44,93), 9 patients (18.0%, 95%
CI 7,36 – 28,64) had a fasting plasma homocysteine between 10 μmol/l to 12 μmol/l and 25 patients (50.0%, 95%CI 36,15 – 63,85) had significantly high
total serum homocysteine values. Among them, 23 patients (46.0%, 95%CI 32,19 – 59,81) had the concentration between 12 – 30 μmol/l and 2 patients
(4,0%, 95%CI -1,43 – 9,43) had the concentration > 30μmol/l. The complex of B vitamin supplementation was recommended at least 2 to 3 months
before conception. In the current study, 40 women (80.0%, 95% CI 68,92 – 91,08) have become pregnant, passed the critical periods for pregnancy loss
and continued the folate intake during the pregnancy.
Conclusions: The prevalence of hyperhomocysteinemia was more in unexplained primary early recurrent miscarriages. The complex of B vitamin
supplementation was recommended at least 2 to 3 months before conception and 40 women (80.0%, 95% CI 68,92 – 91,08) became pregnant, passed the
critical periods for pregnancy loss and continued the folate intake during the pregnancy. |
en_US |